Two companies report ₹1,000 cr of revenue. One will re-earn ~₹950 cr next year before lifting a finger. The other starts at zero and must win every rupee again. The income statements are identical, and the assets couldn't be more different. Grade every revenue line on this ladder:
- Contracted recurring: subscriptions, AMCs, RTA/depository fees, service annuities. Churn is the only enemy. Evidence: deferred revenue, RPO, renewal/persistency rates.
- Auto-repeating behaviour: FMCG staples, razor blades, Costco renewals at ~90%+. There's no contract, but habit does the contracting. Evidence: volume growth, repeat/cohort data, market share stability.
- Re-earned transactional: retail, restaurants, airlines. It's high-frequency with zero obligation, so quality rests on the reason for return. Price trust ranks above promotions.
- Episodic considered purchases: autos, real estate, capital goods, IT project work. Expect multi-year gaps and cyclical timing risk. Order books and pre-sales are the visibility instruments. Read them through book-to-bill and backlog coverage, with thresholds coming in Phase 5.
- One-off / windfall: a milestone payment, a licensing settlement, an exclusivity window (Para-IV 180 days), a pandemic surge, an EPC mega-order, asset sales. It's real cash with zero persistence.
Advertisement
Why does revenue quality matter for valuation?
The cardinal sin is paying a rung-1 multiple for rung-5 earnings. It happens every cycle. Laurus Labs' EBITDA margins swelled to ~30% in the ARV/COVID-contract years and compressed to ~15% by FY24. Peak multiple and peak earnings unwound together. Zoom traded >100× revenue in 2020 on the assumption that pandemic cohorts were rung-1 forever. Pfizer's revenue went from $100bn in 2022 to ~$64bn in 2024 as Comirnaty and Paxlovid receded. None of these were frauds. Investors made classification errors. So split revenue into core-recurring / repeat-behavioural / episodic / windfall. Apply growth and multiples only to the first two. Value windfalls as one-time cash, worth roughly their after-tax amount, the same way a valuation treats non-operating items.
Where to read it: contract liabilities and RPO in the notes. Order book and book-to-bill in Indian capital-goods and IT disclosures. "Revenue from top customer / repeat customers", for which DRHPs are goldmines. Persistency for insurers, and renewal rates for SaaS and Costco. MD&A's own words too, like "one-time" and "exceptional", the ones Phase 2 taught you to Ctrl-F. Then simple year-stacking. Any line that spikes and vanishes is telling you its rung.